| FSLCX | NAESX | FSLCX / NAESX | |
| Total Expense Ratio | 0.86 | 0.17 | 506% |
| Annual Report Gross Expense Ratio | 0.86 | 0.17 | 506% |
| Fund Existence | 28 years | 66 years | - |
| Gain YTD | 13.008 | 14.563 | 89% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 1.34B | 189B | 1% |
| Annual Yield % from dividends | 0.14 | 1.10 | 13% |
| Returns for 1 year | 12.52 | 22.56 | 56% |
| Returns for 3 years | 29.00 | 43.30 | 67% |
| Returns for 5 years | -4.91 | 34.95 | -14% |
| Returns for 10 years | 18.82 | 155.28 | 12% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| VMMSX | 32.15 | 0.39 | +1.23% |
| Vanguard Emerg Mkts Sel Stk Inv | |||
| VRGWX | 936.97 | 7.54 | +0.81% |
| Vanguard Russell 1000 Growth Index I | |||
| GIDWX | 20.04 | 0.13 | +0.65% |
| Goldman Sachs US Eq Div and Premium R6 | |||
| CAVAX | 18.71 | 0.04 | +0.21% |
| SEI Catholic Values Equity F (SCVT) | |||
| RYOIX | 86.56 | -2.00 | -2.26% |
| Rydex Biotechnology Inv | |||